A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gallium 68-DOTATATE (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
Indications Neuroendocrine carcinoma; Prostate cancer
Focus Diagnostic use
Acronyms NEPC Study
Sponsors Novartis Pharmaceuticals

06 Aug 2024 Status changed from not yet recruiting to recruiting.
29 Jul 2024 Planned initiation date changed from 31 Jul 2024 to 31 Aug 2024.
23 Jul 2024 Planned initiation date changed from 18 Jun 2024 to 31 Jul 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com